Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?

Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.

Despite provisional recommendations from the World Health Organization and UNAIDS that cotrimoxazole (CTX) prophylaxis be offered to all individuals living with AIDS, including HIV-positive patients with TB, its routine use in developing countries particularly Africa has been minimal. Concerns were expressed regarding its effectiveness in areas of high bacterial resistance, that its widespread ...

Cotrimoxazole prophylaxis for infants exposed to HIV infection.

1 Clinical Research Fellow, Malawi-Liverpool-Wellcome Trust Clinical Research Programme and Department of Paediatrics, College of Medicine University of Malawi, Malawi ([email protected]). Tel: 265-1-676444; Fax: 265-1-675774. Ref. No. 03-010397 Uncertainty remains about the risks and benefits of implementing guidelines on the use of cotrimoxazole prophylaxis for prevention of HIV-related i...

Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.

Infants with HIV infection are vulnerable to Pneumocystis carinii pneumonia (PCP) during their first year of life. WHO and the Joint United Nations Programme on HIV/AIDS now recommend that all children of HIV-positive mothers receive prophylactic cotrimoxazole against PCP from six weeks of age and continue this therapy until exposure through breast milk ceases-and the infant is confirmed to be ...

Cotrimoxazole Prophylaxis Associated With Reduced Anemia Hazard in HIV-Exposed Infants in a Malaria-Endemic Setting